Phase III Trial of OraTest
PHOENIX-Zila, Inc. has enrolled the first patients in its phase III clinical trial of OraTest, a rinse for detecting severe dysplasia and cancer in patients at elevated risk for oral cancer. Its active ingredient is Zila Tolonium Chloride (pharmaceutical grade toluidine blue). The trial is expected to require fewer than 4,000 high-risk patients, generally requiring a single visit; it will be conducted at approximately 13 investigative sites.
PHOENIX-Zila, Inc. has enrolled the first patients in its phase III clinical trial of OraTest, a rinse for detecting severe dysplasia and cancer in patients at elevated risk for oral cancer. Its active ingredient is Zila Tolonium Chloride (pharmaceutical grade toluidine blue). The trial is expected to require fewer than 4,000 high-risk patients, generally requiring a single visit; it will be conducted at approximately 13 investigative sites.
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer
March 5th 2024Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.
